Idt Australia Limited · ASX:IDT
Idt Australia — Institute of Drug Technology Australia — Shareholder Meeting (October 2006)
12 slides from Idt Australia's shareholder meeting presentation, Oct 27, 2006
Slide 1: Annual General Meeting 27 October 2006
INSTITUTE OF DRUG TECHNOLOGY AUSTRALIA LIMITED Annual General Meeting 27 October 2006
Slide 2: Dr Graeme L Blackman, Chairman and Managing Director
INSTITUTE OF DRUG TECHNOLOGY AUSTRALIA LIMITED Dr Graeme L Blackman CHAIRMAN AND MANAGING DIRECTOR
Slide 3: Key Financial Information
KEY FINANCIAL INFORMATION Full Year Revenue: $25 million Full year NPAT: $3.6 million (Second Half Year Profit Before Tax: record $4.1 million) Dividend Payout Ratio: 95%
Slide 4: Dividend per share (cents)
Dividend per share (cents) 9,00 8.00 7.00 6.00 5.00 4.00 3.00 2.00 1.00 0.00
Slide 5: Outsourcing
a OUTSOURCING Trend to increase outsourcing by major pharmaceutical companies: — More capital in core competencies —Less capital in intensive manufacturing — Speed to market — Second suppliers « Small and medium companies must outsource manufacturing and Clinical trials due to lack of infrastructure
Slide 6: IDT Business Areas
IDT BUSINESS AREAS A: MANUFACTURING: (1) APIs: Commercial manufacture of selected active pharmaceutical ingredients (2) Finished dosage forms: Commercial manufacture of selected finished products including tablets and capsules
Slide 7: Manufacturing Plant
AP| Manufacturing Plant
Slide 8: High Containment Capsule Production Plant
High Containment Capsule Production Plant ..
Slide 9: IDT Business Areas
a IDT BUSINESS AREAS B: DRUG DEVELOPMENT: (1)R&D for local and international companies for new and improved pharmaceutical products. API, Analytical and Drug Products (2) CLINICAL: Early stage clinical development through CMAX clinical trials unit
Slide 10: IDT High Containment R&D facilities
IDT High Containment R&D facilities
Slide 11: Key Business Drivers
a KEY BUSINESS DRIVERS increased finished product manufacturing increased fee for service drug development activity increased clinical trial activity within our Adelaide based CMAX unit
Slide 12: Capital Expenditure ($000)
eS Capital Expenditure ($000) 6000 5000 | 4000 | 3000 4 2000 + 1000 4
Institute of Drug Technology Australia — Shareholder Meeting (October 2006) on 6ix